Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7;69(5):e0008225.
doi: 10.1128/aac.00082-25. Epub 2025 Apr 3.

Evaluation of phenotypic and genotypic methods for detecting KPC variants

Affiliations

Evaluation of phenotypic and genotypic methods for detecting KPC variants

Yasmine Benhadid-Brahmi et al. Antimicrob Agents Chemother. .

Abstract

Klebsiella pneumoniae carbapenemases (KPCs) have spread and diversified extensively. To date, 242 clinical variants have been identified and harbor different hydrolytic capacities, thereby interfering with rapid diagnostic tests. The accurate detection of KPC variants is crucial to guide treatment and control measures in healthcare settings. We constructed KPC variants to assess the mutational impact on detection capacities of resistance-based tests. KPC variants (n = 45) were characterized phenotypically and used to measure the detection sensitivity of KPC detection methods (two lateral flow immunoassays [LFIAs], three hydrolysis tests, three selective culture media, and two PCR-based tests). We identified four antibiotic susceptibility patterns: "KPC-like" (23/45; 51%), "extended-spectrum beta-lactamase-like" (6/45; 13%), "ceftazidimase" (9/45; 20%), and outlier variants with "mixed-profiles" (5/45; 11%). These phenotypes had different impacts on the detection capabilities of hydrolysis tests (0%-100%), LFIA (44%-100%), and selective culture media (0%-100%), highlighting a risk of misdiagnosis for some KPC variants. All variants were detected with PCR-based tests. To detect the maximum of KPC variants, fecal carriage screening requires a combination of selective media targeting resistance to carbapenems, third-generation cephalosporins, and ceftazidime-avibactam. From antibiotic susceptibility testing, resistance to ceftazidime ± avibactam and specific phenotypic profiles should be used as warnings to track the presence of KPC variants. We recommend LFIA as a first-line test, owing to its high sensitivity in detecting KPC variants. Nevertheless, using a combination of tests may remain wise in some situations. The spread of KPC variants remains a significant concern, particularly as reversion to ancestral phenotype could restore carbapenem resistance and lead to therapeutic failure.

Keywords: KPC beta-lactamase; LFIA tests; clinical KPC variants; detection tests; hydrolysis-based tests.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
PCA on the inhibition zone diameters of representative beta-lactams for the 45 strains studied. Each point is labeled with the strain indicated in Table 1. The clusters “ancestral KPC,” “KPC-like,” “ESBL-like,” and “ceftazidimase” are shown in yellow, green, pink, and blue, respectively, and the “mixed” cluster (21, 22, 46, 55, and 72) is shown in red. Arrows indicate higher susceptibility to antibiotics. The first two principal components explained 79.03% (dimension 1—Fig. 1a) and 8.5% (dimension 2—Fig. 1b) of the total variance.
Fig 2
Fig 2
Kiviat diagram showing the distribution of mean inhibition zone diameters for the principal antibiotic molecules tested, by major phenotypic profile: “ancestral KPC,” “KPC-like,” “ceftazidimase,” and “ESBL-like.” AMX, amoxicillin; TZP, piperacillin-tazobactam; CTX, cefotaxime; CAZ, ceftazidime; ETP, ertapenem; IMP, imipenem; MEM, meropenem. Diameters: millimeters; blue crosses: EUCAST breakpoints (11).

Similar articles

Cited by

References

    1. Munoz-Price LS, Quinn JP. 2009. The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin Infect Dis 49:1739–1741. doi:10.1086/648078 - DOI - PubMed
    1. Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, Jacquier H, Birgy A. 2022. Klebsiella pneumoniae carbapenemase variants resistant to ceftazidime-avibactam: an evolutionary overview. Antimicrob Agents Chemother 66:e0044722. doi:10.1128/aac.00447-22 - DOI - PMC - PubMed
    1. Ding L, Shen S, Chen J, Tian Z, Shi Q, Han R, Guo Y, Hu F. 2023. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev 36:e0000823. doi:10.1128/cmr.00008-23 - DOI - PMC - PubMed
    1. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs (Abingdon Engl) 73:159–177. doi:10.1007/s40265-013-0013-7 - DOI - PubMed
    1. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2018. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs (Abingdon Engl) 78:65–98. doi:10.1007/s40265-017-0851-9 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources